Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CLPP | Q16740 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100600 | 1.00 | CYP11B1 (0.40) | CYP11B1CYP11B2PDE2ASCN9AHSD11B1 | |
| SCHEMBL4090649 | 0.90 | GRM5 (0.50) | PDE2AHSD11B1GRM5CLPPPDE3A | |
| SCHEMBL4090653 | 0.90 | GRM5 (0.50) | PDE2AHSD11B1GRM5CLPPPDE3A | |
| SCHEMBL4092422 | 0.89 | PROKR1 (0.41) | CYP11B1CYP11B2PDE2AHSD11B1GRM5 | |
| SCHEMBL4092434 | 0.89 | PROKR1 (0.41) | CYP11B1CYP11B2PDE2AHSD11B1GRM5 | |
| SCHEMBL1970038 | 0.89 | GRM5 (0.44) | PDE2ASCN9AHSD11B1GRM5CLPP | |
| SCHEMBL1974636 | 0.89 | GRM5 (0.44) | PDE2ASCN9AHSD11B1GRM5CLPP | |
| SCHEMBL1971050 | 0.88 | HSD11B1 (0.45) | PDE2ASCN9AHSD11B1GRM5CLPP | |
| SCHEMBL1972321 | 0.88 | HSD11B1 (0.43) | PDE2ASCN9AHSD11B1GRM5CLPP | |
| SCHEMBL1971534 | 0.88 | HSD11B1 (0.45) | SCN9AHSD11B1GRM5CLPPRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | claimed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | CYP11B1 1834/4885CYP11B2 1780/4885PDE2A 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.